[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - … Cancer Research, 2020 - ncbi.nlm.nih.gov
… Afatinib had a superior tendency in terms of CNS-PFS, and cumulative incidence of CNS
failure compared with gefitinib or erlotinib. However, our study, as a retrospective study, has …
failure compared with gefitinib or erlotinib. However, our study, as a retrospective study, has …
[HTML][HTML] … in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective study
K Yoshida, S Kanda, H Shiraishi, K Goto… - Journal of Thoracic …, 2019 - ncbi.nlm.nih.gov
… differences between the gefitinib and erlotinib treatment groups in the present study. This …
of next-line chemotherapy in both groups (gefitinib group: 69.4%; erlotinib group: 69.2%). In …
of next-line chemotherapy in both groups (gefitinib group: 69.4%; erlotinib group: 69.2%). In …
Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
WX Hu, JC Peng, Y Wang, H Jin… - International Journal of …, 2022 - Taylor & Francis
… included in this study retrospectively. All patients were administered with gefitinib plus anlotinib
… Citation14 Therefore, we noticed that bevacizumab plus erlotinib combination therapy …
… Citation14 Therefore, we noticed that bevacizumab plus erlotinib combination therapy …
A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study
CS Lee, I Ahmed, E Miao, S Chung… - Journal of Oncology …, 2022 - journals.sagepub.com
… trial validated the efficacy of osimertinib to platinum-based combination chemotherapy plus
pemetrexed, in advanced NSCLC patients who developed resistance to erlotinib or gefitinib …
pemetrexed, in advanced NSCLC patients who developed resistance to erlotinib or gefitinib …
Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small …
T Kishikawa, T Kasai, M Okada, I Nakachi… - Thoracic …, 2020 - Wiley Online Library
… in a phase III trial (FLAURA),12 osimertinib showed a longer PFS than gefitinib or erlotinib
when … Therefore, we retrospectively evaluated patient characteristics, treatment status, and the …
when … Therefore, we retrospectively evaluated patient characteristics, treatment status, and the …
… non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study
K Kashiwabara, S Fujii, S Tsumura… - … of Cancer Research and …, 2021 - Springer
… Herein, we present the results of our retrospective analysis data to evaluate the survival
benefit of first-line EGFR-TKI therapy, as compared to that of cytotoxic chemotherapy or best …
benefit of first-line EGFR-TKI therapy, as compared to that of cytotoxic chemotherapy or best …
… and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis
Y Sun, M Wu, M Zhou, X Luo, Y Guo, H Bai, Z Zhang… - BMC cancer, 2020 - Springer
… confirmed by another recent retrospective study based on a … , one phase III trial evaluated
the adjuvant use of gefitinib in … Another randomized, phase II, open-label, multicenter study (…
the adjuvant use of gefitinib in … Another randomized, phase II, open-label, multicenter study (…
[HTML][HTML] … erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective …
LJ Hung, PC Hsu, CT Yang, CHS Kuo… - Aging (Albany …, 2024 - ncbi.nlm.nih.gov
… effectiveness and safety of afatinib, gefitinib, and erlotinib for elderly patients with epidermal
… , this study aimed to describe the effectiveness and safety of afatinib, gefitinib, and erlotinib …
… , this study aimed to describe the effectiveness and safety of afatinib, gefitinib, and erlotinib …
Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: a real-world multicentric cohort analysis from India
A Garg, U Batra, P Choudhary, D Jain… - Current Problems in …, 2020 - Elsevier
… were included in this retrospective multicentric data analysis (… in this study actually had
poorer outcomes with gefitinib (hazard … is more cost effective than erlotinib, further information is …
poorer outcomes with gefitinib (hazard … is more cost effective than erlotinib, further information is …
[HTML][HTML] Comparison of effectiveness of Gefitinib, Erlotinib, and Afatinib in advanced non-small cell lung cancer patients with EGFR mutation positive in Indonesian …
N Sutandyo, A Hanafi, M Jayusman - Chinese journal of lung …, 2019 - ncbi.nlm.nih.gov
… retrospective cohort study of 88 NSCLC patients with EGFR mutation positive treated with
gefitinib (n=59), erlotinib (… The result of this study provides evidence that gefitinib, erlotinib, and …
gefitinib (n=59), erlotinib (… The result of this study provides evidence that gefitinib, erlotinib, and …
相关搜索
- cell lung carcinoma retrospective multicenter study
- effect of gefitinib retrospective cohort study
- multicenter study real world treatment outcomes
- efficacy of gefitinib retrospective analysis
- gefitinib or erlotinib somatic egfr mutations
- gefitinib erlotinib and afatinib
- retrospective exploratory study safety of gefitinib
- gefitinib therapy multicenter phase ii trial
- retrospective study non-small cell lung cancer
- multi-institute retrospective study
- gefitinib and erlotinib in patients
- multicenter study lung cancer
- retrospective study real world data
- retrospective study erlotinib therapy in patients
- retrospective exploratory study anlotinib for patients
- gefitinib and erlotinib first line setting